Search

Introduction: Chronic obstructive pulmonary disease (COPD) is associated with poor prognosis in non‐small cell lung cancer (NSCLC) patients. There are limited data about the impact of severe‐to‐very severe COPD on prognosis in patients with NSCLC receiving first‐line chemotherapy. Objectives: To investigate whether severe‐to‐very severe COPD impacted survival of patients with NSCLC receiving first‐line chemotherapy. Methods: A retrospective review was performed on 513 consecutive NSCLC patients receiving first‐line chemotherapy between February 2014 and May 2018. Prognostic impact of severe‐to‐very severe COPD was analysed using regression analyses. Results: Totally 258 NSCLC patients (118 non‐COPD, 96 mild‐to‐moderate COPD and 44 severe‐to‐very severe COPD) were evaluated retrospectively. Kaplan‐Meier analysis showed that the median overall survival times in the severe‐to‐very severe COPD, mild‐to‐moderate COPD and non‐COPD groups were 14.0 months [95% confidence interval (CI): 11.0‐17.0], 18 months (95% CI: 14.8‐21.2) and 19 months (95% CI: 15.3‐22.7), respectively. The difference was significant between patients with severe‐to‐very severe COPD and those without COPD (χ2 = 6.8, P = 0.009) and between patients with severe‐to‐very severe COPD and those with mild‐to‐moderate COPD (χ2 = 4.0, P = 0.045). Multivariate analysis showed that survival time was significantly shorter in the severe‐to‐very severe COPD group than in the non‐COPD group (adjusted hazard ratio: 1.876, 95% CI: 1.161‐3.030, P = 0.01) and mild‐to‐moderate COPD group (adjusted hazard ratio: 1.782, 95% CI: 1.046‐3.034, P = 0.033). Conclusion: Severe‐to‐very severe COPD may worsen the prognosis of NSCLC patients who received first‐line chemotherapy. [ABSTRACT FROM AUTHOR]

Introduction: Chronic obstructive pulmonary disease (COPD) is associated with risk of venous thromboembolism (VTE) events. A detailed understanding of which clinical features of COPD increase risk of VTE events is needed. Objectives: To investigate the association between features of COPD and risk of venous thromboembolism. Methods: A retrospective observational clinical study was conducted on 551 consecutive COPD patients visiting the Department of Respiratory and Critical Care Medicine of Tianjin Chest Hospital between February 2014 and April 2018. Finally, 151 patients were eligible for inclusion. Of these, 29 patients had COPD with VTE and 121 patients had COPD without VTE. Patient informations regarding age, gender, BMI, smoking history, smoking status (package/year), COPD‐related symptoms, lung function, number of acute exacerbations and imaging visual emphysema were gathered. Results: Among the 29 VTE patients, 18 patients had PE and five had DVT, while 6 patients had simultaneous PE and DVT. There were statistically significant differences in GOLD grade, Imaging visual emphysema, and frequent acute exacerbations between the two groups. Multivariate logistic regression analysis showed that after adjustment for gender, age, BMI and smoking history, there were statistically significant for visible emphysema (OR = 3.54, 95% CI: 1.13‐11.08; P = 0.03) and GOLD grade (OR = 1.77, 95% CI: 1.04‐3.01; P = 0.035), but not for frequent acute exacerbations (OR = 1.65, 95% CI: 0.62‐4.38; P = 0.31). Conclusions: Visual emphysema is an independent risk factor for VTE events and the risk of VTE in COPD patients increases with the degree of airway obstruction. However, there is no evidence of an association between exacerbation frequency and VTE events. [ABSTRACT FROM AUTHOR]